Complete Genomics Partners with Integrated DNA Technologies to Establish New Ecosystem of NGS Products

October 18, 2023 11:00 PM AEDT | By Cision
 Complete Genomics Partners with Integrated DNA Technologies to Establish New Ecosystem of NGS Products
Image source: Kalkine Media

SAN JOSE, California, Oct. 18, 2023 /PRNewswire/ -- Complete Genomics, Inc., a pioneering genomic sequencing company, today announced its partnership with Integrated DNA Technologies (IDT), a global genomics solutions provider, to develop an ecosystem of advanced compatible products based on Complete Genomics' innovative DNBSEQ™ sequencing platforms.

"High-throughput sequencing is a multi-step process that demands high accuracy and performance while maintaining an easy-to-use workflow. This partnership with IDT will combine its sample/library preparation expertise with Complete Genomics sequencing which provides a simplified and optimized workflow for a range of high value applications," said Rob Tarbox, Complete Genomics' Vice President of Product and Marketing, "With a growing install base of our DNBSEQ platforms*, we are excited to provide streamlined reagents for our partners and customers to use."

With a mission to accelerate the pace of genomics, IDT has been enabling genomics laboratories and researchers in high-throughput sequencing, CRISPR genome editing, synthetic biology, digital PCR, RNA interference, and more with its proprietary technologies since 1987. Its relationship with MGI, parent company of Complete Genomics, started in June 2018.  With Complete Genomics' technical support, IDT has empowered users in library preparation through conversion workflow and data generated by targeted sequencing.

Earlier this year, Complete Genomics joined the IDT Collab Network as one of its founding members. The program aims to unite researchers and industry partners under a single, impactful research network to foster learning, collaboration, and future technology development. With an increasing installation base of DNBSEQ sequencing platforms, the companies are enhancing their partnership by optimizing IDT's technology for Complete Genomics' sequencing platforms. The two partners will work together to develop a range of library preparation solutions that can directly be sequenced on DNBSEQ sequencing platforms without the need for library conversion.

As the NGS market continues to mature, more users are driving the need for faster, better and more innovative solutions to help them answer complex questions to their oncology, immunology and infectious disease projects," said Linda De Jesus, VP/GM, Global Head of Commercial at IDT. "We're proud to be joining forces with Complete Genomics to accelerate the speed of genomics research and ensure users of its DNBSEQ sequencing platform have access to the NGS tools they need to advance important discoveries."

Joined by a strategic partnership of top expertise and cutting-edge technologies, Complete Genomics and IDT are set to take high-throughput sequencing to the next level with a simplified workflow that is highly compatible, flexible, and efficient. With emerging needs in the field, the new ecosystem of compatible products represents a significant leap in providing users with more flexible, accessible and impactful Complete Genomic solutions, empowering the next scientific breakthrough.

About Complete Genomics

Complete Genomics is a pioneering life sciences company that provides novel, end to end DNA sequencing solutions. It has been at the forefront of high throughput sequencing technology development since its inception in 2005. Our products have powered over 6,200 publications across a wide array of applications. To learn more, visit www.completegenomics.com.

* For Research Use Only. Not for use in diagnostic procedures.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next

Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.